Remarkable advances have occurred since the Series 3 Fascicle published in 1995 with paradigm shifts in every dimension of our understanding of lung tumors including clinical, radiologic, histopathologic, cytopathologic, immunohistochemical, molecular and therapeutic aspects. The molecular revolution leading to effective targeted therapies and breakthroughs in immunotherapy for lung cancer have led to novel approaches incorporating the concept of personalized medicine for patients who historically had little hope. These advances have strengthened the place of pathologists to play a central role in the multidisciplinary team that is now needed to properly diagnose and manage lung cancer patients.
• William D. Travis, MD, Director, Thoracic Pathology, Attending Thoracic Pathologist, Memorial Sloan Kettering Cancer Center, New York.
• Andrew G. Nicholson , MBBS, MA, DM, FRCPath, Consultant Histopathologist, Royal Brompton and Harefield Hospitals NHS Foundation Trust, and Honorary Professor of Respiratory Pathology, National Heart and Lung Division, Imperial College, London, UK.
• Kim R. Geisinger , MD, Professor of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
• Elisabeth Brambilla, MD, PhD, Emeritus Professor of Pathology, University Grenoble Alpes-CHUGA, Grenoble, France.